Curis Lifesciences IPO Details: Everything You Should Know about 

Check Expert’s Verdicts on Curis Lifesciences IPO

Curis Lifesciences IPO will be open for bidding from 7th November to 11th November. It is a book-building issue of 27.52 crore shares. The issue is entirely a fresh issue of 22,00,000 shares. The IPO is expected to be listed on the NSE and SME with a tentative listing date of 14th November 2025.

Curis Lifesciences IPO Details

The Curis Lifesciences IPO is expected to take place from 7th November 2025 to 11th November 2025. The face value of Curis Lifesciences IPO shares is ₹2 per share, and the IPO price is set at ₹120 to ₹128 per share.

MUFG Intime India Limited is the registrar of the Curis Lifesciences IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below.

Curis Lifesciences IPO Details 

Curis Lifesciences IPO Share Reservation

Curis Lifesciences IPO is a bookbuilding IPO issue of 27.52 Crore shares. Curis Lifesciences Limited Shares will be listed on the NSE and the SME. Furthermore, SEBI has specified the share reservation criteria for different investor categories.

Curis Lifesciences IPO GMP 

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Would you like to receive live updates on the Curis Lifesciences IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

As of November 5, 2025, the Curis Lifesciences IPO GMP stands at ₹0 per share, indicating that the share is likely to list at ₹128 on its tentative listing date, November 14, 2025.

GMP data is subject to change based on market trends and sentiments. Please verify the live GMP status before applying for the Curis Lifesciences IPO GMP. Stay informed with Univest for real-time insights into IPOs and their GMP trends. 

Curis Lifesciences IPO Review

Review the detailed Curis Lifesciences IPO review for a thorough understanding of its potential to deliver listing gains. The Curis Lifesciences IPO review will help you invest effectively to avoid significant losses. Explore more to make an informed Investment decision on this IPO.

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Therefore, it is crucial to comprehend the business’s economic performance and trends before applying for the Curis Lifesciences IPO.

Curis Lifesciences Limited’s revenue increased by 38% from ₹4.87 crores in March 2024 to ₹49.65 crores in March 2025. Moreover, the company’s PAT increased by 25% from ₹4.87 crores to ₹6.11  crores. Investors can analyse other relevant factors and make a decision accordingly.

Curis Lifesciences Limited’s IPO has shown consistent revenue growth, indicating the company’s financial stability. Moreover, brokers, investors, and RAs have a positive outlook for Curis Lifesciences’ IPO on its tentative listing day.

Technical Analysis

Some technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Curis Lifesciences IPO

The P/E ratio of Curis Lifesciences Limited’s shares is 12.44, and its Earnings Per Share (EPS) is 10.29. Thus, the Curis Lifesciences Limited IPO can deliver gains on its tentative listing day, 14th November 2025

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Curis Lifesciences Limited are subject to change after the IPO. Refer to the table below for post-issue updates on these two metrics. 

Curis Lifesciences IPO Subscription Status

 The subscription status for the Curis Lifesciences IPO is yet to be announced. Stay informed on this passage to check the live Curis Lifesciences IPO subscription status. 

About the Curis Lifesciences Limited Company Overview 

Curis Lifesciences Limited was established in 2010 and is a prominent pharmaceutical company that engages in the development, manufacturing, and distribution of various products. It has manufacturing units globally and domestically, through licenses and on a contract basis, and it has its own brand marketing. 

• Experienced Promoters and Management Team
• Wide range of Products
• Strategic Location of Manufacturing Facility
• Scalable Business Model
• Quality assurance

Curis Lifesciences Limited Financials

The company’s financial analysis is essential before applying for Curis Lifesciences Limited’s IPO. Look at the table to learn about Curis Lifesciences Limited’s financials. 

Explanation

Curis Lifesciences Limited’s revenue increased by 38% from ₹4.87 crores in March 2024 to ₹49.65 crores in March 2025. Moreover, the company’s PAT increased by 25% from ₹4.87 crores to ₹6.11  crores. Investors can analyse other relevant factors and make a decision accordingly.

Curis Lifesciences IPO Promoter Holdings

Have a look at the table below to check the holdings of Curis Lifesciences Limited’s promoters: Mr Dharmesh Dashrathbhai Patel, Mr Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala and Mr Jaimik Mansukhbhai Patel.

Note: The value will be calculated using Equity Dilution = Share Holding Pre-Issue –  Share Holding Post-Issue.

Curis Lifesciences IPO Objectives

The primary objective of the Curis Lifesciences IPO is to raise ₹27.52 crore. However, before applying for the IPO, you should be aware of its secondary objectives. Explore them below

• Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities.
• Capital Expenditure towards Construction of a Storage Facility
• Pre-payment/Repayment of outstanding Secured Loans
• Product Registrations in other countries
• Funding our Working Capital Requirements
• General Corporate Purposes

Should I Invest in Curis Lifesciences IPO?

Explore the pros and cons of Curis Lifesciences IPO to decide whether to apply for it or avoid it. These pros and cons might help you understand the IPO’s potential to deliver profits in the coming decades.

Pros of Curis Lifesciences IPO

• The company’s revenue has shown impressive growth in recent years.
• It has a diversified product portfolio
• Scalability in the business model
• Experienced promoters and management team
• Assured high-quality product

Cons of the Curis Lifesciences IPO

• High risk of regulatory laws in the pharmaceutical sector
• Any delay in the government order will slow down the order
• High pricing competition
• Huge capital investment
• Client concentration risk

How to Invest in the Curis Lifesciences IPO?

Please follow the steps outlined below to apply for a position at Curis Lifesciences IPO Limited.

• Step 1: Conduct thorough research on the Curis Lifesciences IPO, including GMP status, subscription status, issue size, lot size, and other relevant details. 
• Step 2: Open a demat account with Univest to gain real-time insights into GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
• Step 3: Place a bid for two lots of 2,000 shares, valued at ₹2,56,000.
• Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Curis Lifesciences IPO across multiple demat accounts to increase your chances of allotment. 

How to Check Curis Lifesciences IPO Allotment Status?

You can check for the Curis Lifesciences IPO allotment in different ways. These include NSE and the registrar portal. Follow the steps below to check your allotment status online.

Check On NSE

• Visit the NSE Official Website.
• Navigate to the IPO Allotment Section. 
• Select Equity as the issue type. 
• Choose the Curis Lifesciences IPO.  
• Choose whether to proceed with the PAN number or the application number.
• Submit your details to get the allotment status online. 

Check On the Registrar Portal

• Visit the registrar portal. 
• Click on the allotment option.
• Fill in the required details.
• Click on the submit button to know your Curis Lifesciences IPO allotment status.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts 

Curis Lifesciences IPO is a bookbuilding IPO of ₹27.52 crore. The shares of Curis Lifesciences IPO Limited will be listed on the NSE and SME on its tentative listing date of 14th November 2025. Researching the Curis Lifesciences IPO, including its GMP status and reviews, is highly recommended to secure the profitability you desire. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Stay informed with Univest to get regular updates on the Curis Lifesciences IPO, GMP, subscription, and more!

FAQs on Curis Lifesciences IPO

How is the Curis Lifesciences IPO?

Ans. As of  5th November 2025, the Curis Lifesciences IPO GMP (Grey Market Premium) stands at 0. It indicates that the estimated listing price could be ₹128 per share. It is a book-building IPO of 27.52 crore shares. The face value of each share of Curis Lifesciences IPO Limited is ₹10.

What is Curis Lifesciences’ IPO price?

Ans. The Curis Lifesciences IPO price range is ₹120.00 to ₹128.00 per share. Retail investors can apply for a minimum of 2 lots, each consisting of 2,000 shares, worth ₹2,56,000. Moreover, HNIs are required to bid for a minimum of 3 lots (3,000 shares) worth ₹3,84,000.

Is the Curis Lifesciences IPO a good investment?

Ans. Curis Lifesciences Limited’s revenue increased by 38% from ₹4.87 crores in March 2024 to ₹49.65 crores in March 2025. Moreover, the company’s PAT increased by 25% from ₹4.87 crores to ₹6.11  crores. Investors can analyse other relevant factors and make a decision accordingly.

Who will be the registrar of the Curis Lifesciences IPO?

Ans. According to recent updates, MUFG Intime India Private Limited will be the registrar responsible for managing allotment and refund procedures. For any queries regarding the Curis Lifesciences IPO GMP, allotment, and refund, you can contact MUFG Intime India Private Limited at ipo.helpdesk@linkintime.co.in or +91-22-4918 6270.

What is the issue size of the Curis Lifesciences IPO?  

Ans. Curis Lifesciences IPO is a book-building issue of ₹27.52 crore. Moreover, the IPO is set to open on 7th November 2025 and close on 11th November 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Curis Lifesciences IPO, wait for the Curis Lifesciences IPO RHP and Curis Lifesciences IPO DRHP. Conduct your research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Upcoming IPOs

Current & Previous IPOs

Read Our Articles on the Best Stocks

Tech Stocks in India to Invest in 2025 | Tech Sector Stocks 

Best Battery Stocks in India to Invest in 2025 | Battery Sector Stocks 

Best Shipping Stocks in India to Invest in 2025 | Shipping Sector Stocks 

Paint Stocks in India to Invest in 2025 | Paint Sector Stocks 

Paper Stocks in India to Invest in 2025 | Paper Sector Stocks 

Best Semiconductor Stocks in India 2025 

Best Large Cap Stocks in India 2025 

Green Energy Penny Stocks

Best Cement Stocks To Invest in India

Also Explore

Univest Screeners